Pharmacogenetics in electroconvulsive therapy and adjunctive medications
Hooman Mirzakhani1,2,3, Martijn S van Noorden4, Jesse Swen3
1Channing Division of Network Medicine, Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.
Pharmacogenomics
|June 27, 2015
Summary
Pharmacogenetics can improve the safety and effectiveness of electroconvulsive therapy (ECT) for mental health conditions. Understanding genetic influences may also reveal new psychiatric treatment strategies.
Area of Science:
- Psychiatry
- Pharmacogenetics
- Neuroscience
Background:
- Electroconvulsive therapy (ECT) is effective for treatment-resistant depression and other mental illnesses.
- Individual responses to psychotropic medications vary significantly.
- Pharmacogenetics offers insights into personalized drug sensitivity and efficacy.
Purpose of the Study:
- To review the role of pharmacogenetics in the safety and efficacy of ECT.
- To explore the application of pharmacogenetics in psychiatric patients undergoing ECT.
- To highlight potential molecular mechanisms for novel psychiatric treatments.
Main Methods:
- Literature review of pharmacogenetic studies related to ECT.
- Analysis of evidence for pharmacogenetics in psychiatric disorders treated with ECT.
- Synthesis of current understanding of genetic influences on ECT response.
Main Results:
- Pharmacogenetics influences patient sensitivity and response to ECT and adjunctive medications.
- Clinical application of pharmacogenetics can enhance ECT safety and efficacy.
- Understanding genetic factors may identify new therapeutic targets for psychiatric disorders.
Conclusions:
- Pharmacogenetics plays a crucial role in optimizing ECT outcomes.
- Personalized pharmacogenetic approaches are essential for effective ECT treatment.
- Further research into pharmacogenetics can advance psychiatric treatment paradigms.
Related Concept Videos
01:30Electroconvulsive Therapy
2.1K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.1K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
119
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
119
01:27Pharmacogenetics of Drug Metabolism: Overview
137
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
137
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
01:26Psychosis: Goals of Pharmacotherapy
668
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
668
01:29Pharmacogenetics and Pharmacogenomics: Overview
162
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
162